1. FDA OKs an eighth use for JNJ’s Xarelto — Roche’s Rituxan shows superiority in autoimmune skin condition — Sun Pharma launches dry eye disease treatment in US — See more on our front page news

    TRY TWO WEEKS OF OUR EMAIL NEWS HEADLINES FOR FREE
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Ocular Theraputix

Discussion in 'Ophthalmology' started by anonymous, Jan 25, 2017 at 7:45 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Anyone know about the company? Good product?
     
  2. anonymous

    anonymous Guest

    Product not yet approved, company is doing a contract sales force for at least the first year. Interviewing process is ridiculous & apparently they have no idea dripless is taking over the market bc they think hospitals & ASCs are going to pay $400 for this?!
     
  3. anonymous

    anonymous Guest

     
  4. anonymous

    anonymous Guest

    Or it's never coming out...FDA issued CRL yesterday due to manufacturing issues. Even if it does do they really think there is a market for this anymore? Apparently this pharma blow hards have 0.0 connections to surgical reps bc they would have told them the dropless ship has sailed. Inserting a punctual for slow release drug would have been a step backwards and a more expensive one at that!?!

    What will the arrogant midwestern manager JB do now that he is laid off again?! He was such a tool in the interviewing process and obviously had a huge chip on his shoulder for never being able to make it from Alcon pharma to surgical.